Sophiris (SPHS) Multi-month Ascending Broadening Wedge - BullishSPHS is in a multi-year ABW and with the latest partial decline, in addition to other important fundamental and technical factors, it will likely breakout upwards - To infinity and beyond!!
Sophiris
SPHS Oversold, Filling the Gap, cash/share > share priceSophiris Bio had a Phase III drug trial test showing the drug was not effective and the market overreacted. The chart has a cash/share value (mrq) of $1.74, the float is 16.78 Million Shares (note today's volume alone is a large part of that), so with a tiny float, more cash per share on hand than the market price, and upcoming results for new Phase III results for other products, one can see why people are buying this up right now.
